Skip to content
Back to news
ResearchNovember 21, 2026

Merck Drops Blood Cancer Drug It Got in $2.7B ArQule Buyout

Merck Drops Blood Cancer Drug It Got in $2.7B ArQule Buyout: PharmoniQ news card

Merck is ending all work on nemtabrutinib, an oral blood cancer drug it got when it bought ArQule. The company said on Nov. 17 that an outside data monitoring committee reviewed a phase 3 study and raised concerns that the drug's benefits may not outweigh its risks.

What happened

Nemtabrutinib is an investigational BTK inhibitor that does not bind permanently to its target. Merck was testing it in chronic lymphocytic leukemia (CLL), SLL and other blood cancers under a program called BELLWAVE.

The trigger was BELLWAVE-011, a phase 3 study in people with CLL or SLL who had not been treated before. After the committee's review, Merck looked at the full data set and agreed with its view. Merck then decided to stop the whole program, not just that one study.

  • Studies stopped: BELLWAVE-011, plus two other phase 3 studies, BELLWAVE-008 and BELLWAVE-010.
  • Size of the lead trial: BioSpace reported that Merck started BELLWAVE-011 in 2023, planned to enrol 1,200 patients and expected its main results in 2032.
  • Patients: Merck said it is telling study investigators, and it advised patients in the trials to talk with their study team and doctor about next steps.
  • Data: The company said analyses are still under way and it plans to share results with the scientific community.

Merck did not give details on what the committee saw. Dr. Marjorie Green, senior vice president and head of global oncology clinical development at Merck Research Laboratories, said the company will keep working on treatments for people with blood cancers.

Why it matters

Nemtabrutinib was the main asset in Merck's $2.7 billion purchase of ArQule at the end of 2019, according to BioSpace. At the time it was in early testing, where it had shown a manageable safety profile and early signs of activity against tumours.

The decision takes Merck out of the race for non covalent BTK inhibitors in CLL. Eli Lilly is already in that space with Jaypirca, which came from its $8 billion buyout of Loxo Oncology, BioSpace noted.

The setback also lands as Merck looks for new sources of growth. BioSpace cited a BMO report from September that puts $33 billion in Keytruda revenue at risk from patent losses starting in 2028.

What it means for people in the industry

Merck did not announce job cuts or site changes tied to this decision. The near term work falls on trial sites, which Merck is now informing, and on patients, who are advised to talk through their options with their study team and doctor.

Things to watch: the full data when Merck releases it, and what Merck does next with the rest of its blood cancer pipeline.

See open pharma jobs in the US and Canada

Sources

Check Your Supplement Interactions

Use our AI-powered checker to analyze supplement safety and interactions.

Open Interaction Checker →

Comments (0)

Leave a comment

Your email is not shown. Please keep it civil and do not give medical advice. Comment rules

This article is for informational purposes only and does not constitute medical or investment advice. It was written with AI assistance from the sources listed above. Check the original sources before relying on any detail.